Introduction
The considerable psychological, emotional and financial burden on individuals, carers and society from dementia and Alzheimer's disease (AD) is universally accepted, 1, 2 and widely predicted to increase substantially in the coming decades. 2, 3 Following the initial report over 30 years ago, 4 a substantial literature has accumulated showing the loss of cholinergic neurons in the basal forebrain and their projections in the neocortex, hippocampus and amygdala, which results in impairment of higher cognitive functions. 5, 6 At present, approved pharmacological therapies for the treatment of AD, which target this cholinergic deficit, have shown only symptomatic benefits. 7 However, not all individuals respond to cholinesterase inhibitor (ChEI) treatment. 8 Identification of clinical characteristics that predict response to treatment would be useful and may well improve cost effectiveness.
Genetic susceptibility factors for disease have important and practical implications, such as the enhanced understanding of disease aetiology and the early identification of individuals at high risk of developing familial disease. More recently, interest in the field of pharmacogenomics has grown, and also the prospect of targeting the most effective treatment for the individual. 9 The major genetic risk factor for late-onset (non-familial) AD is carriage of the apolipoprotein E e4 allele (APOE e4). 10 The presence of APOE e4 is associated with a greater cholinergic deficit 11 and rate of cognitive decline 12 than in non-carriers of APOE e4, suggesting a likelihood of poorer clinical response to ChEI treatment. Gender may interact with APOE genotype in cognitive decline and, therefore, may also be a predictor of response. 13 Several studies have evaluated APOE genotype and gender as predictors of cognitive response to ChEI therapy for AD. Results have been inconsistent. Initial reports suggested a better response to tacrine in individuals who were noncarriers of APOE e4, 11, 14 particularly in women. 15 However, other researchers have reported that the presence of APOE e4 is associated with improved outcome with ChEI therapy. [16] [17] [18] [19] [20] Several studies did not find that APOE genotype influenced treatment response. [21] [22] [23] [24] [25] [26] [27] [28] Gender, either alone or in interaction with APOE genotype, was not found to influence response to ChEIs. 18, 23, 26, 27 Several lines of evidence indicate that butyrylcholinesterase (BuChE) has a significant role in cholinergic function, both in the normal brain and in AD. 29 Variation in the BuChE gene (BCHE) can lead to reduced activity of the enzyme. 30 The most common reported polymorphism is the K variant (BCHE-K). 31 Homozygous individuals have approximately 30% reduced plasma BuChE activity 31 and show a slower rate of cognitive decline. 32, 33 Lehmann et al. 34 published the initial report of an association of BCHE-K with increased risk of AD. Several groups, including our own, 35 independently replicated this association. [36] [37] [38] Other investigators found no association. [39] [40] [41] Some groups have reported a protective effect of BCHE-K genotype on the risk of AD. [42] [43] [44] A meta-analysis of all published association studies indicates that BCHE-K does not influence the risk of AD (odds ratio (OR) 1.08, 95% confidence interval (CI) 0.96-1.22) (http://www.alzgene. org). However, it has been suggested that the inconsistency among the reported studies might be owing to other genetic and non-genetic interactions that limit the influence of BCHE-K to a subset of susceptible people. 45 Meta-analysis indicates that BCHE-K increases the risk of AD in men aged over 75 years who are carriers of APOE e4.
45
BCHE-K is associated with improved attention compared with the wild-type BCHE gene and with a slower rate of cognitive decline. 32 BCHE-K has also been found to correlate with a slower rate of cognitive decline in severe AD (Mini-Mental State Examination (MMSE) p8) than the wild-type gene, but not at less severe stages of the disease. 46 The BCHE genotype has also been evaluated as a predictor of response to ChEI therapy. Secondary analyses of a randomized controlled trial comparing rivastigmine and donepezil in moderate AD suggested that rivastigmine, a dual acetylcholinesterase and BuChE inhibitor, 47 was associated with improved outcomes compared with donepezil, which inhibits acetylcholinesterase only, in subjects younger than 75 years 48 who did not carry the BCHE-K variant. 49 Another report suggested no difference in response to donepezil or rivastigmine treatment according to BCHE genotype. 50 Further investigation of the response to ChEI therapy across a range of AD severities associated with APOE and BCHE genotypes is warranted. 29 The objective of this study was to determine whether APOE or BCHE genotype predicts cognitive response to ChEI therapy.
Materials and methods
This study was approved by the Research Ethics Committee of the Queen's University of Belfast. Written informed consent was obtained from all subjects or carers. Subjects were recruited from the Belfast City Hospital Memory Clinic. Subjects underwent a standardized assessment, including a structured interview, physical examination, routine biochemical screening, computerized tomography scan of the brain and an electrocardiogram, by a consultant or specialist registrar with experience in assessment scales and making a diagnosis of AD. A detailed corroborative history was taken from the carer (usually a family member) using a proforma and recording details of cognitive, behavioural and psychiatric symptoms, as well as past medical history, family history of dementia and other disorders, social history, including alcohol consumption and smoking, and drug history. The assessment included the MMSE, 51 Hachinski Ischaemic Scale, 52 Barthel Index of Daily Living 53 and Global Deterioration Scale. 54 Diagnosis of probable AD was made using the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition guidelines in conjunction with the criteria of the National Institute of Neurological and Communicative Diseases and Stroke/ Alzheimer's Disease and Related Disorders Association. 55 Subjects were excluded if there were findings suggestive of mixed dementia, vascular dementia, Parkinson's related dementia, dementia with Lewy bodies or other types of non-AD dementia. Subjects were also excluded if they had a diagnosis of AD, but were not suitable for treatment with ChEI. Reasons for exclusion were contraindications to ChEI treatment, patient or carer refusal, questionable compliance, severity of disease and severe side effects, resulting in the subject being unable to take the drug for longer than 4 weeks.
To determine the response to ChEI therapy, three further assessments were made. These were timed to record evidence of an early response (3-9 months) ('visit 2'), late response (9-15 months) ('visit 3') and very late response (15-24 months) ('visit 4'). At each visit, an assessment of the patient's cognitive response (using MMSE), activities of daily living (using Barthel scale) and caregiver's impression of response was made. In addition, occurrences of side effects, change to medication doses, change to the subject's home circumstances or change to concomitant medications were recorded. Adverse events were self-reported.
Genomic DNA was extracted from peripheral blood leucocytes by the salting-out method, 56 quantified by nanodrop spectrophotometry, diluted with sterile water to 50 ng ml À1 and amplified using PCR. 57, 58 Genotyping was performed for APOE and BCHE as described previously. 59, 60 Samples were coded and the procedure performed with the investigator blinded to clinical data.
Demographic and response variables were compared between groups using Pearson's w 2 test (categorical variables) and the independent-samples t-test or one-way analysis of variance (continuous variables). Improvement in MMSE score at visit 2 was deemed an early cognitive response and improvement or no decline in MMSE from visit 1 to visits 3 or 4 was deemed a late cognitive response. To analyse the relationship between genotype and response to treatment, subjects were divided into two groups based on the presence or absence of the APOE e4 allele and BCHE-K variant, respectively. Subgroup analyses were carried out in categories defined by baseline MMSE to determine the relationship between genotype and response to treatment according to disease severity. Mild AD was defined as an MMSE X21 2 and moderate-to-severe AD as an MMSE p15. Deviations from Hardy-Weinberg equilibrium in the distributions of the APOE and BCHE genotypes were assessed using the w 2 goodness-of-fit test. All analyses were performed using the statistical package SPSS version 17.0 (SPSS Inc., Chicago, IL, USA), with the significance level set at Po0.05 (two-tailed).
Results
Three hundred and seven potential subjects were screened, of whom 142 were excluded owing to non-AD diagnosis, subject or carer refusal, or contraindication to ChEI treatment. Of the 165 included subjects, 92 (55.8%) were female. Mean age of the cohort at initial assessment was 74.2 years (range 56-89) and mean age of onset was 71.1 years (range 46-86). The mean MMSE at baseline was 20.5 (range 7-28). Other demographic features are shown in Table 1 .
During the follow-up period nine subjects died. No deaths were ascribed to ChEI treatment. At the end of the study, another 47 subjects were lost to follow-up-34 discharged to primary care on subject or carer request or owing to repeated non-attendance at the Memory Clinic and 13 referred to the psychiatry of old age service. Of these 47, 17 had stopped ChEI treatment and 30 were still taking ChEI treatment at last follow-up. At the end of the study, 109 of the original cohort were still attending the clinic.
Data were gathered for up to 2 years after the initial recommendation to commence ChEI treatment. All 165 subjects reached visit 2, 146 (88.5%) visit 3 and 81 (49.1%) visit 4. The number of subjects initially started on the respective ChEIs was donepezil 100; galantamine 45; and rivastigmine 17. Within 4 weeks of starting treatment, five subjects were switched to an alternative ChEI owing to side effects (four with severe gastrointestinal symptoms and one with acute psychotic episode).
Cognitive response Eighty subjects (48.5%) were early responders and 81 (49.1%) late responders. Those lost to follow-up were deemed non-responders. This was to avoid bias by favouring cognitive response to ChEI treatment. Those who dropped out of the study likely had more severe AD, had developed behavioural and psychiatric symptoms requiring referral to psychiatry of old age, or had died.
APOE genotype and cognitive response Table 2 shows the distribution of APOE genotypes within the cohort. Results were not available from eight subjects. Genotype frequencies did not deviate from Hardy-Weinberg equilibrium. The frequencies correlate with previously published data in the genetically homogeneous population of Northern Ireland. 61 Gender, level of education, duration of disease and baseline MMSE did not differ significantly between the group that carried at least one e4 allele and the group that did not. Table 3 shows the cognitive response to ChEI treatment at the follow-up visits as the mean change in MMSE score from the initial visit. At visit 3, the mean change in MMSE score was significantly better in those who carried an e4 allele compared with non-carriers. When the cohort was stratified according to disease severity, those classified as mild AD (MMSE X21) (n ¼ 96, no results for four subjects) showed a significant correlation between APOE genotype and early (visit 2) and late cognitive response (visit 3) to ChEI treatment, as assessed by change in MMSE from the initial visit (Table 4) . Early responders were signi- ficantly more likely to be APOE e4 carriers than non-APOE e4 carriers in the full cohort (w 2 ¼ 10.3, P ¼ 0.002) and in those with mild AD (w 2 ¼ 9.4, P ¼ 0.003). Late responders were also significantly more likely to be APOE e4 carriers than non-APOE e4 carriers in the full sample (w 2 ¼ 7.3, P ¼ 0.01) and in those with mild AD (w 2 ¼ 10.5, P ¼ 0.002). Further analysis using logistic regression found that the particular ChEI agent used had no effect on APOE genotype and cognitive response to ChEI treatment. Gender, alone or in conjunction with APOE genotype, did not affect cognitive response to ChEI treatment.
BCHE genotype and cognitive response Genotype frequencies for BCHE are shown in Table 5 and do not deviate from Hardy-Weinberg equilibrium. Results were not available for 10 subjects. Gender, level of education, age of onset, duration of disease and baseline MMSE did not differ significantly between the group with the BCHE-K variant and the group without. Overall, no significant interaction was found between BCHE genotype and cognitive response to ChEI treatment. On stratification of the cohort according to disease severity, subjects with moderate-to-severe AD (MMSE p15) (n ¼ 24, no results for one subject) who carried the BCHE-K variant had a significantly better late cognitive response (visit 3) to ChEI treatment than those who were homozygous for the wildtype allele, as assessed by change in MMSE from the initial visit (Table 6 ). BCHE genotype did not predict whether cognitive response to the individual ChEI agent commenced. There was no interaction between the presence of both APOE e4 and BCHE-K on cognitive response to ChEI treatment.
Discussion
This study reports on a cohort of predominantly community-dwelling subjects with AD attending a Memory Clinic with longitudinal data on cognitive response to ChEI therapy, extending out to 24 months of maximal follow-up. As assessed by the change in MMSE, cognitive response to ChEI therapy was found to be significantly better in the mild stage in APOE e4 carriers and in the moderate-to-severe stage in BCHE-K carriers, as compared with non-carriers.
The observed APOE genotype frequency distributions are in line with previous reports with over-representation of the e4 allele in the AD group compared with normal controls (Table 2) . 62 Presence of the e4 allele was associated with better cognitive response to ChEI treatment on long-term follow-up (9-15 months) ( Table 3 ). In those with mild disease (MMSE X21), presence of the e4 allele resulted in a better short-(3-9 months) and long-term cognitive response ( Table 4 ). The benefit did not persist at very long-term follow-up (15-24 months), perhaps owing to greater variability in the timing of visit 4 compared with visits 2 and 3 and the smaller number of subjects reaching this follow-up Abbreviation: BCHE, BuChE gene.
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CE Patterson et al visit. The MMSE examines a restricted range of cognitive function and has limited ability to detect clinically meaningful changes at very early and late stages of AD (ceiling and floor effects). 63, 64 However, it is widely used in clinical settings, such as reported here, in mild-to-moderate disease severity.
The current results are consistent with previous reports, which have suggested that carriage of APOE e4 is predictive of early and late response to ChEI treatment. After 6 months of treatment with tacrine in 78 subjects with mild-tomoderate AD, APOE e4 carriers had a better response than non-carriers. 16 Another report found the e4 allele to confer cognitive benefit after 12 months of treatment with tacrine. 17 These studies used change in MMSE as the measure of response, but did not report baseline MMSE. Oddoze et al. 18 showed that an improved early response to donepezil occurred in those subjects carrying an e4 allele. However, response was not affected by APOE status in mild disease, 18 which was defined as MMSE 18-24 inclusive as opposed to X21 in this study. In another study of donepezil treatment in AD, a beneficial late effect (12 months) on cognition was found in the APOE e4 carriers. 19 In a study of Korean subjects with AD, a beneficial late response (48 weeks) to donepezil, as measured by the ADAS-Cog subscale, was found in APOE e4 carriers. 20 Other reports in the literature have not found APOE e4 genotype to influence cognitive response to ChEI therapy. 15, 23, 24, 26, 28 Explanations for these inconsistent findings include aspects of study design, such as small sample size, single versus multiple drug dosing, lack of randomization, variable outcome measures used, variable follow-up periods and variable definitions of response to ChEI treatment; pharmacokinetic and pharmacodynamic characteristics of the different ChEIs used; and genetic heterogeneity in the trial populations. Earlier work had suggested that the greater cholinergic deficit 11 and rate of cognitive decline 12 associated with the carriage of APOE e4 might result in a poorer response to ChEI treatment. However, our finding of an improved response to ChEI treatment with APOE e4 carriage is plausible and consistent with other subsequent treatment studies. [16] [17] [18] [19] [20] APOE e4 carriers have higher levels of acetylcholinesterase, 65 and the cholinergic deficit is less marked in AD, potentially leading to better response to treatment than in non-APOE e4 carriers.
BCHE-K carriers have a higher concentration of senile plaques and ChE-positive plaques in the temporal cortex than those with the wild-type gene. 66 It may be hypothesized that BCHE-K carriers show a different response to ChEI therapy than do non-carriers. The BCHE-K variant is associated with lower plasma BuChE activity (B30% lower in homozygotes) compared with the wild type. 31 However, this may not correlate with the brain BuChE activity. A recent neuropathological study reported that in a group of patients with dementia of various aetiologies, BuChE activity measured in the temporal cortex is higher in those with the BCHE-K variant compared with the wild type. 67 There was a marked overlap between the wild-type and K variant groups, although a dose-response relationship was noted in the number of K alleles and cortical BuChE activity. 67 An earlier neuropathological study in subjects with dementia with Lewy bodies, not AD, showed a significant correlation between BuChE activity in the temporal cortex at post mortem and more rapid cognitive decline during life, which was independent of disease severity, duration and age. 33 Moreover, in a predominantly dementia with Lewy bodies cohort, the BCHE-K variant is associated with enhanced attention at baseline and poorer response to rivastigmine treatment, compared with those who did not carry the K variant and had impaired attention at baseline. 32 Disease progression in those with the K variant was only 60% of that seen in the wild-type group. 32 Another study found that in severe AD, as defined by an MMSE p8, the rate of cognitive decline was lower in those subjects with the K variant. 46 This study found significantly better late cognitive response in BCHE-K carriers in moderate-to-severe disease (MMSE p15) ( Table 6 ). Results were not significant at very late follow-up; however, perhaps owing to the small number of subjects. Of note, in Holmes et al.'s study, 46 cognitive decline was not associated with the BCHE-K variant in moderate-to-severe dementia (MMSE 9-16 inclusive). One other report found that BCHE genotype did not influence response to ChEI treatment. 50 However, only change in MMSE was reported and not disease severity, making comparison with previous reports and this study difficult. A recent study has suggested an explanation for these seemingly incongruous findings. 68 BCHE-K was found to be unstable with reduced serum catalytic activity as compared with the wild-type enzyme, which may induce elevated acetylcholine levels. 68 In addition, however, BCHE-K was much less efficient in stopping accumulation of amyloid-b peptide into fibrils in vitro than the wild-type protein, suggesting a risk for AD. 68 Clearly, further work is required to clarify the relationship between BCHE genotype and BuChE activity in both blood and brain and the mechanisms by which BCHE variants may influence risk for AD and response to ChEI treatment. A strength of this study is the 'real-world' setting in the routine clinical practice of a Memory Clinic, increasing the applicability of the findings. However, the setting is also a limitation as this influenced the rating scales used and the variable time between follow-up visits for the subjects. Subjects who discontinued treatment were also more frequently non-attenders for follow-up, introducing bias in the assessment of response rates. Subjects who were lost to follow-up often required referral to psychiatry of old age services, suggesting progression of AD. This supports the classification of these subjects as 'non-responders'. The ChEIs prescribed at the clinic (donepezil, galantamine and rivastigmine) may have beneficial effects on cognition other than ChE inhibition. Owing to the small numbers of each agent prescribed, results were analysed for the group as a whole. It was not possible to determine, therefore, whether the effect of genotype on cognitive response is determined by the particular agent used. On stratification of this predominantly community-dwelling cohort by disease severity, the number of moderate-to-severe subjects reaching 'very late' follow-up is small.
Pharmacogenomics is an emerging field. The ability to predict whether an individual will respond to treatment would be a great advance, particularly in AD, in which a substantial minority of patients do not respond to ChEI therapy and are currently exposed to potential adverse effects at considerable expense to health and social care systems. This study suggests that genotype testing for APOE and BCHE may be helpful to clinicians when discussing therapeutic strategies for subjects with AD and their carers. The sponsor had no role in this study, except for providing funding. The decision to submit for publication was that of the authors alone.
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